DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].